top of page

Nano team

Currently, gold nanoparticles employed in biomedical applications use sulfur–gold linkages to protect the GNP from decomposition and enable targeting of cancerous tissues. However, this linkage is vulnerable to oxidation, resulting degradation & loss of selective targeting. To address this issue C2MCI is developing robust, oxidation-resistant carbon-based ligands, resulting in remarkably improved stability and novel luminescence properties. Our research will be transformative for hard-to-treat cancers and will dramatically improve outcomes for radiation therapy in cancers with high mortality rates, such as pancreatic cancer, melanoma, and renal cell carcinoma.

​

If you are interested in learning more about our current projects at the Nano level please contact our Managing Director, Jyoti Kotecha, or email a member of the research team. 

bottom of page